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Abstract 
Serum is an essential requirement for the growth and long-term survival of human endothelial cells, even in the presence of such 
defined elements uch as polypeptide growth factors and hormones. A polypeptide from fetal bovine serum was isolated and characterized 
on the basis of long-term survival of human endothelial cells in serum-free culture. The endothelial cell viability maintaining factor has 
been purified to homogeneity by a combination of polyethylene glycol precipitation, hydroxylapatite, gel permeation and reverse-phase 
high performance liquid chromatography. The final purified endothelial cell viability maintaining factor has a molecular weight of 65 000 
(reduced) and has been identified as bovine apolipoprotein H by amino-terminal mino acid sequence analysis and Western blot analysis. 
Endothelial cell viability maintaining factor improved a long-term viability of human endothelial cells at maximal concentrations of 2.5-5 
/~g protein/ml in serum-free medium. 
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I. Introduction 
Growth and maintenance of vascular endothelial cells 
play an important role in a variety of physiological and 
pathological processes uch as angiogenesis, wound heal- 
ing, atherosclerosis, tumor growth and embryonic develop- 
ment [1-3]. Thus, factors regulating the growth and main- 
tenance of endothelial ceils may be of importance in 
understanding these processes. 
In recent years, several potent endothelial cell growth 
factors and mitogens have been isolated and characterized. 
These polypeptide growth :factors include acidic and basic 
fibroblast growth factors [4,5] from neural tissues, 
platelet-derived endothelial cell growth factor [6,7] and 
vascular endothelial cell growth factor which was first 
isolated from cultured pituixary folliculostellate cells [8,9]. 
Abbreviations: AFGF, acidic fibroblast growth factor; FBS, fetal 
bovine serum; EGF, epidermal growth factor; PEG, polyethylene glycol 
4000; HUVEC, human umbilical vein endothelial cells; EC-VMF, en- 
dothelial cell-viability maintaining factor; TFA, trifluoroacetic acid; 
MeCN, acetonitrile; Apo H, apolipoprotein H.
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However, it is noteworthy that serum is an absolute re- 
quirement for optimal growth and long-term maintenance 
of human endothelial cells, even in the presence of these 
polypeptide growth factors. 
It has been reported [10] that the conditioned medium of 
differentiated hepatoma cells (Hep G2) allowed human 
endothelial cells to grow and survive in a serum-free 
medium containing epidermal growth factor, high density 
lipoprotein and an extract of bovine neural tissues. Two 
polypeptides (ECGF-2a and ECGF-2b), which improved 
survival and growth of human endothelial cells in serum- 
free medium, were isolated from the conditioned medium 
of human hepatoma cells [11]. The first 25 NH:terminal 
residues of ECGF-2a and first 49 residues of ECGF-2b 
were determined and identified as human pancreatic secre- 
tory trypsin inhibitor and urinary glycoprotein proteinase 
inhibitor (HI-30/EDCI), respectively [11]. Both proteins 
are tumor-associated proteinase inhibitors and are absent 
or at low levels in normal serum, but abundant during 
acute inflammatory diseases and cancer. Further experi- 
ments [12] demonstrated that ECGF-2a appeared to be a 
survival factor for human endothelial cells and ECGF-2b 
had a moderate stimulatory effect on DNA synthesis of 
these cells in a serum-free medium. Even in the presence 
of ECGF-2a and ECGF-2b, however, human endothelial 
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cells started to detach from the surface of culture vessel 
after more than 3 days in culture [11] which resulted in the 
failure of these cells to survive. 
In this study, we purified and characterized a potent 
endothelial cell viability maintaining factor from fetal 
bovine serum, which promoted the long-term survival of 
human endothelial cells in a serum-free medium. 
stimulation of each sample was calculated using the for- 
mula below: 
Cell number in test medium 
% stimulation = X 100 
Cell number in control medium 
2.3. Purification of EC-VMF 
2. Materials and methods 
2.1. Materials 
Nutrient medium MCDB 107 [13] and acidic fibroblast 
growth factor (aFGF) from bovine brain were generous 
gifts of Kyokuto Pharmaceuticals (Tokyo, Japan). Human 
apolipoprotein H and rabbit antiserum against human apo- 
lipoprotein H which can cross-react with bovine apolipo- 
protein H are kind gifts from Dr. Eiji Matsuura, Yamasa 
shoyu, Choshi, Japan. Fetal bovine serum (FBS) was 
purchased from Flow Laboratories (North Ryde, Australia). 
Recombinant human epidermal growth factor (EGF) was 
from Wakunaga Pharmaceuticals (Osaka, Japan). Bovine 
lung aprotinin (pancreatic trypsin inhibitor), heparin and 
bovine pancreas trypsin (Type XII-S) were obtained from 
Sigma (St. Louis, MO). Cellgen (collagen Type I-AC) was 
from Koken (Tokyo, Japan). Polyethylene glycol 4000 
(PEG) was a product of Merck (Darmstadt, F.R. Germany). 
Human umbilical vein endothelial cells (HUVEC) were 
from Kurabo (Osaka, Japan). 
2.2. Bioassay of endothelial cell-viability maintaining fac- 
tor (EC- VMF) 
Stock cultures of human umbilical vein endothelial cells 
(HUVEC) were maintained in medium MCDB 107 con- 
taining 10 ng/ml EGF, 10 ng/ml aFGF, 10 /xg/ml 
heparin and 2% (v/v)  FBS in 25 cm 2 plastic tissue culture 
flasks (MS-20050, Sumitomo Bakelite, Tokyo, Japan) 
coated with 10 /xg/ml Cellgen using modification of 
previously described procedures [12]. 
For the bioassay of EC-VMF a serum-free medium 
MCDB 107 containing 10 ng/ml EGF, 10 ng/ml aFGF, 
10/xg/ml heparin and 0.5/zg/ml aprotinin was used as a 
control medium. The cells were trypsinized and seeded at a 
density of 5 X 103 cells/well with 1 ml of a control 
medium containing test materials or FBS into Cellgen 
coated 24-well culture plates (Falcon 3047, Becton Dickin- 
son, Lincoln Park, NJ). Cells were incubated in a humidi- 
fied atmosphere of 95% air/5% CO 2 at 37°C for 5 days 
without a change of medium, unless otherwise noted, and 
then harvested with 0.25% (w/v) trypsin-0.02% (w/v) 
EDTA in Ca 2÷, Mg2+-free phosphate-buffered saline 
(PBS-). Cell numbers were determined in a Coulter 
counter (Coulter Electronics, Luton, UK). The percent 
Fractionation of fetal bovine serum (FBS): FBS was 
fractionated by precipitation with polyethylene glycol 4000 
(PEG). All operations were carried out at 4°C. 400 ml of 
FBS was pre-buffered with 10 mM phosphate buffer (PB) 
(pH 6.8) using a 4:1 ratio. A solution of 40% (w/v)  PEG 
in 10 mM PB (pH 6.8) was added slowly with constant 
stirring to the buffered FBS to make a final concentration 
of 15% PEG. The resultant precipitate was collected by 
centrifugation at 12000 rpm for 30 min and then redis- 
solved in PBS- for bioassay or in 75 mM PB (pH 6.8) for 
further purification. This preparation was designated as 
SP15. The amount of protein was determined by the 
Bradford method [14] using BSA as a standard. 
Hydroxylapatite chromatography (HAC): The SPI 5 ma- 
terial (20-30 mg protein) was loaded at room temperature 
onto a hydroxylapatite column (100 X 8 ram; Hydroxyl- 
apatite-MP Hibar RT1008, Kanto Chemicals, Tokyo, 
Japan) previously equilibrated with 10 mM PB (pH 6.8). 
The column was washed with 7 ml of the equilibration 
buffer and eluted with a linear gradient of sodium phos- 
phate from 10 to 300 mM of pH 6.8 over 60 min at a flow 
rate of 1 ml/min. Effluent was collected as each fraction 
of 1.0 ml per tube and then 4 or 5 tubes were pooled. The 
combined fractions were concentrated and the solvent was 
exchanged to PBS- for bioassay or following further 
purification using Centricon-30 microconcentrator 
(Amicon, Danvers, MA). 
Gel permeation chromatography (GPC): The active 
fraction from the HAC was applied to a Superose 12 HR 
10/30 column (300 X 10mm; Pharmacia Biotechnology, 
Uppsala, Sweden) equilibrated with PBS- and eluted at a 
flow rate of 0.5 ml/min with the same buffer. Each cycle 
of the GPC used 4-5 mg of protein of the active fraction 
from the previous step. Fractions of 1 ml were collected 
and tested for EC-VMF activity. The column was precali- 
brated with the following molecular weight marker pro- 
teins (Pharmacia Biotechnology, Uppsala, Sweden): 
chymotrypsinogen A (25,000), ovalbumin (43 000) bovine 
serum albumin (67 000), ferritin (440 000) and tryroglobu- 
lin (669 000). 
Reverse-phase high performance liquid chromatog- 
raphy (RP-HPLC): The active fraction from the GPC was 
acidified using 0.1% (v/v)  trifluoroacetic acid (TFA) and 
applied to Vydac protein C4 column (Type 214 TP 54, The 
Separation Group, Hesperia, CA) previously equilibrated 
with 30% acetonitrile (MeCN) and 0.1% TFA. 150-300 
/xg protein was loaded per cycle of RP-HPLC. The column 
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was washed with the equilibration buffer for 11 min and 
the protein sample was eluted with a linear gradient of 
MeCN from 30% to 60% over 30 min. Each 0.5 ml of 
fraction was collected and immediately dried by vacuum 
concentration. The dried fractions were then redissolved in 
PBS- for the bioassay of EC-VMF. 
2.4. Amino-terminal mino acid sequence analysis 
The amino-terminal mino acid sequence of EC-VMF 
was determined using an automated gas phase microse- 
quencer (Model PSQ-1, Shimadzu, Kyoto, Japan). Purified 
EC-VMF (300 pM) was applied on the microsequencer. 
After Edman degradation, the released phenylthiohydan- 
toin-derivatized amino acids were identified in an on-line 
PTH-amino acid analyzer with RP-HPLC (Wako Pure 
Chemicals, Osaka, Japan). 
2.5. Electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel elec- 
trophoresis (SDS-PAGE) was carried out using gradient 
gels from 10% to 20% polyacrylamide (Daiichi Pure 
Chemicals, Tokyo, Japan) After electrophoresis, bands of 
protein were detected by Coomassie brilliant blue R-250 
staining. The molecular weight was calculated based on 
the mobilities of standard proteins (low range; Bio-Rad 
Laboratories, Richmond, CA): rabbit muscle phospho- 
rylase b (M r 97400), bovine serum albumin (M r 66 200), 
hen egg white ovalbumin (M r 42700), bovine carbonic 
anhydrase (M r 31 000), and soybean trypsin inhibitor (M r 
21 500). 
2.6. Western blotting 
Purified EC-VMF wa,; subjected to SDS-PAGE and 
transferred to a nitrocellulose membrane by the method of 
Towbin et al. [15]. The membrane was incubated for 2 h at 
room temperature with rabbit antiserum against human apo 
H at 1:200 dilution, and bound antibody was visualized 
with peroxidase-conjugated antibodies against rabbit IgG 
and an immunostain HRP kit (IS-50B; Konica, Tokyo, 
Japan). The molecular weight was calculated from the 
mobilities of pre-stained M r marker proteins (low range; 
Bio-Rad Laboratories, Richmond, CA). 
3. Results 
3.1. Fractionation of growth-promoting activity in FBS 
FBS was sequentially precipitated and fractionated at 
0-1%, 1-3%, 3-5%, 5--7.5%, 7.5-10%, 10-15%, 15- 
20% and 20-35% (w/v)  PEG. A considerable amount of 
mitogenic activity for HUVEC existed in the precipitates 
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Fig. 1. Effect of SPI5 on human endothelial cell proliferation i  serum-free 
medium. HUVEC (5X 103 cells/well) were cultured with a control 
medium containing SPI5 fraction at the indicated concentrations, closed 
circle, for 5 days. Solid bar represents the growth of HUVEC in the 
medium containing 2% FBS (v/v,  920 /xg protein/ml). Data are the 
mean of triplicate xperiments. 
from fractions at 5-7.5%, 7.5-10% and 10-15% (w/v)  
PEG. As PEG precipitation provided a convenient way of 
eliminating other non-stimulatory proteins in FBS, the 
precipitate of 10-15% PEG was used as a starting material 
(SP15) for the further purification of EC-VMF. The pro- 
tein recovery of SP15 fraction was among 5-10% of the 
total FBS protein (6.4% average). The SP15 stimulated 
HUVEC proliferation in a dose-dependent manner in 
serum-free medium (Fig. 1). The mitogenic activity of the 
SP15 was maximal at a concentration of 290 /xg/ml and 
half-maximal dose (ECso) was approximately 70 /xg/ml. 
In the complete absence of serum, HUVEC failed to 
survive more than 2 days in culture, but the cell yield 
(1.98 X 10 4 cells/well) at a maximal dose of SP15 was 
almost equal to that (2.02 × 10 4 cells/well) in 2% FBS 
(protein concentration: 920 /xg/ml). Only one-third the 
amount of SP15 compared to serum protein was required 
to elicit the maximal stimulation of endothelial cell prolif- 
eration. 
3.2. Purification of the EC-VMF 
Since SPI5 contained the majority of growth-promoting 
activity for HUVEC, this fraction was subjected to a 
hydroxylapatite column. EC-VMF activity bound to the gel 
in 10 mM phosphate buffer (pH 6.8), and was eluted in the 
fractions between 0.15 to 0.20 M phosphate buffer (pH 
6.8) (Fig. 2A). Although the growth-promoting activity 
was spread out over a wide range of fractions, the majority 
of the activity was present in fractions 8 (HA8) and 9 
(HA9). The recovery of the activity in this step was 
contained in 8.3% of the total protein applied. Fractions 8 
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Fig. 2. Isolation of EC-VMF from PEG precipitate fraction SP15. (A) 
Hydroxylapatite column chromatography (HAC). Twenty mg of SP15 
was loaded onto a hydroxylapatite column, and eluted with a linear 
gradient, dotted line, of sodium phosphate. Twenty-/xl aliquots of each 
pooled fraction, fraction number indicated in the open column, was 
examined for bioassay of EC-VMF as described in Section 2. Increase in 
cell number, open column, was expressed as a percent of cell number in a 
control medium (0.34× 10 3 cells per well). Data are the mean of tripli- 
cate wells. (B) Gel permeation chromatography (GPC). A half ml (4.6 mg 
protein) of the active fractions (8 and 9) from HAC were loaded onto the 
column. 10-/zl aliquots of each concentrated fraction were used for 
bioassay. Increase in cell number, open column, was expressed as a 
percent of cell number in a control medium (0.40 × 10 3 cells/well). Data 
are the mean of triplicate wells. Arrowheads indicate M r of standard M r 
marker protein. (C) RP-HPLC of EC-VMF activity. The active fraction 
(fraction 6) of total protein 212 p~g from GPC was loaded onto a column, 
and eluted with a linear gradient of MeCN, dotted line. 20-/xl aliquots of 
each fraction was tested for its endothelial cell-viability maintaining 
activity. Black column represents he active protein fraction. 
Table 1 
Summary of purification of endothelial cell-viability maintaining factor 
Purification step Total protein Maximal dose Yield Purification 
(mg) ( /xg/ml)  (%) rate 
PEG precipitation 1377 290 100 1 
HAC 120 65 39.2 4.5 
GPC 8.52 11 16.3 26.4 
C4 RP-HPLC 0.49 2.5 4.1 116 
(HA8) and 9 (HA9) from the HAC were then used for 
GPC. Fraction 6 (GP6) at M~ 35-40 kDa contained a
remarkable amount of EC-VMF activity (Fig. 2B). The 
recovery of activity for this step was 7.1%. Final purifica- 
tion of the EC-VMF was achieved using Vydac C a RP- 
HPLC. The active fraction (GP6) from GPC was injected 
onto a Vydac C4 column and a single peak of EC-VMF 
activity was obtained at 35% MeCN (Fig. 2C). This frac- 
tion contained 5.7% of the protein in the GP6 fraction. A 
separate analysis of the molecular weights of EC-VMF 
using SDS-PAGE under reduced and non-reduced condi- 
tions indicated apparent molecular weights of 65 000 and 
58 000, respectively (Fig. 4A). 
A summary of the purification procedure from 1,377 
mg protein of PEG-precipitated fraction (SP15) corre- 
sponding to approximately 400 ml FBS is shown in Table 
I. The EC-VMF protein was purified 116-fold with an 
overall yield of 4.1%. 
3.3. Amino-terminal mino acid sequence of EC-VMF 
The first 25 amino-terminal mino acid residues of 
EC-VMF were determined by a gas-phase microsequencer. 
All determined residues of EC-VMF showed complete 
identity with bovine apolipoprotein H and 88% identity 
with human apolipoprotein H (Fig. 3). The sequence was 
compared to sequences in the protein data base, SWISS- 
PROT 27, of European Molecular Biology Laboratory. An 
undefined residue at position 4 which could not be de- 
tected by the analytical procedures employed, correlated 
with cysteine residue of apo H. 
This result was confirmed by Western blotting of EC- 
VMF using rabbit antiserum against human apo H (Fig. 
4B). Rabbit antiserum cross-reacted to both proteins of 
EC-VMF (M r 65 000) and human apo H (M~ 53 000). 
1 5 I0 15 20 25 
EC-VMF GRT X P K P DELp  F S TVVP L KR  T Y E P G 
Bov ine  apo H R T X P K P D E L P F S T V V P L K R T Y E P 
apo . R T x P K P V ~  P r S r v V P L K~- -~Y E P Human 
Fig. 3. Amino-terminal mino acid sequences of purified EC-VMF and its 
homology with bovine and human apo H. The amino-terminal amino acid 
sequence of EC-VMF was compared with those of bovine apo H and 
human apo H [16]. Boxed residues represent identical amino acids. 
X = unidentified residue. 
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Fig. 4. SDS-PAGE and Western blotting of active fraction from C 4 
RP-HPLC. (A) 200 and 400 ng/lane of EC-VMF were applied to 
SDS-PAGE under educing (lane 1) and non-reducing (lane 2) conditions, 
respectively. M, M r marker proteins. (B) Western blotting of EC-VMF 
(lane 1) and human apo H (lane 21) by rabbit antiserum against human apo 
H. M, Pre-stained M r marker proteins. 
3.4. Effect of purified EC-VMF on the cell viability of 
HUVEC 
Very few HUVEC survived in serum-free, control 
medium after 5 days in culture. However, the addition of 
purified EC-VMF supported the dose-dependent stimula- 
tion of endothelial cell-viability in this serum-free medium 
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Fig. 5. Dose-dependent effect of EC-VMF on the long-term maintenance 
of HUVEC in a serum-free medium. HUVEC (5 X 103 cells/well) were 
seeded and cultured in a control raedium containing the indicated concen- 
trations of EC-VMF. After 5 days in culture, cells were trypsinized and 
counted by a Coulter counter. Increase in cell number was expressed as a 
percent of cell number in a control medium (0.58 × 103 cells/well). Data 
are the mean of triplicate wells. 
on cell attachment and cell viability of 
Factor added Cell number ( X 103/well) 
after cultured for 
1 day 5 days 
Control 3.62 _ 0.14 0.71 + 0.22 
EC-VMF (5 ~g/ml)  3.86+0.24 3.36+0.35 
FBS (2% V/V)  4.47+0.31 15.80+ 1.56 
HUVEC (5 × 103 cells/well) were seeded into Cellgen-coated 24-well 
tissue culture plates containing control medium described in Fig. 1 in the 
presence of the indicated factors. Cultures were incubated for 1 day and 5 
days and then the cells were harvested and counted. Data are the 
mean _ S.D. of triplicate wells. 
(Fig. 5). The EC-VMF significantly increased the viability 
of HUVEC at a concentration as low as 0.5 /zg/ml and 
was optimal at concentrations of 2.5-5.0 /xg/ml. The 
effect of EC-VMF and FBS on cell attachment and long- 
term cell viability of HUVEC was determined (Table 2). 
The attached cell number (3.86 x 103 cells/well) in the 
presence of EC-VMF was almost equal to that (3.62 X 10 3 
cells/well) in control medium after 24 h in culture. FBS 
(2% v /v )  slightly increased the attached cell number 
(4.47 X l0  3 cell/well). After 5 days in culture, only few 
cells (0.71 X 10 3 cells/well) survived in the control 
medium, while the addition of EC-VMF greatly improved 
cell survival of HUVEC (3.36 × 10 3 cells/well). FBS- 
containing medium elicited the HUVEC proliferation and 
resulted in 15.8 × 10 3 cells/well after 5 days in culture. 
4. Discussion 
The present study has demonstrated the purification and 
characterization f an endothelial cell viability maintaining 
factor (EC-VMF) from fetal bovine serum. The EC-VMF 
was purified with a combination of PEG precipitation, 
HAC, GPC, and RP-HPLC. Analysis by SDS-PAGE 
showed that the purified factor is a single chain polypep- 
tide with an apparent M r of 65 000 and 58 000 Da under 
reduced and non-reduced conditions, respectively. EC- 
VMF was characterized as bovine apolipoprotein H ac- 
cording to analysis of amino-terminal mino acid sequence 
and antigenicity. This factor stimulated the long-term sur- 
vival of human endothelial cells in a serum-free medium. 
Maximal effect of the EC-VMF was obtained at concentra- 
tions of 2.5-5 /xg/ml. 
The first 25 amino acids on the amino terminal se- 
quences were identical with the published sequence of 
bovine apo H and showed 88% homology with human apo 
H (Fig. 3) [16,17]. Human apo H, also called fl2-glyco- 
protein I, was first isolated by Schlutze et al. [18] and its 
complete amino acid sequence was determined by Lozier 
et al. [19]. It is a single peptide, composed of 326 amino 
acids and has a unique amino acid sequence containing 
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abundant proline (8.3%) and cysteine (6.2%) residues and 
multiple internal disulfide bonds. Mehdi et al. [20] have 
cloned and sequenced apo H cDNAs from both human 
liver and a human hepatoma cell line (Hep G2). Human 
apo H is found associated with very low density lipopro- 
teins, high density lipoprotein, and chylomicrons, as well 
as in serum [21]. The mean plasma level of human apo H 
is about 200 #g/ml  [22]. Although very little is known 
about the major functional roles of apo H, it may be 
involved in apolipoprotein C-II activation of lipoprotein 
lipase [23], diminish adenylate cyclase activity in platelets 
after binding to their membranes [24] and/or inhibit blood 
coagulation [25]. 
An apolipoprotein H-like protein was isolated from fetal 
bovine serum by affinity chromatography on heparin-Sep- 
harose, ion exchange chromatography, gel permeation and 
reverse-phase HPLC [26]. The final yield of the protein 
isolated from 100 ml of serum was approx. 230 /~g as 
compared to 123 /xg of EC-VMF per 100 ml serum 
isolated using our purification procedure (Table 1). Our 
purification resulted in an apparent l l6-fold increase in 
specific activity with a 4.1% recovery from the PEG-treated 
FBS. If EC-VMF is like apo H, the low recovery may be 
partly due to it being a unique glycoprotein that consists 
mainly of /3-sheets and random coils, with little a-helical 
character to its secondary structure [19,27]. In contrast 
with the positive effect of EC-VMF on HUVEC mainte- 
nance in this study, apo H-like protein purified from FBS 
inhibited the DNA synthesis of fetal calf liver erythroid 
cells [26]. The inhibitory action of the bovine apo H-like 
protein, however, seems to be limited to certain cell types, 
because it was inactive in cultures of mouse 3T3 fibrob- 
lasts [26]. 
The addition of EC-VMF showed a potent stimulation 
of HUVEC cell survival in serum-free medium (Table 2). 
The tumor-associated proteinase inhibitor (ECGF-2a), 
which is identical with aprotinin, was found to support he 
survival of HUVEC in a serum-free medium for 2-3 days 
in culture [11]. In the presence of aprotinin, EC-VMF was 
able to maintain the cell-surviving activity of HUVEC for 
more than 5 days in a serum-free medium (Table 2). 
Nevertheless, EC-VMF had no significant stimulation on 
DNA synthesis of the cells in our preliminary experiments. 
Further investigation should be carried out on the 
molecular mechanisms as to how EC-VMF influences cell 
survival. EC-VMF in plasma may be important for the 
long-term survival of endothelium in vivo. A system using 
serum-free defined medium containing this factor, would 
be useful for studying the mechanism and transport of 
biologically active molecules. 
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